Predicting Thrombosis Risk in Rheumatoid Arthritis: The Combined Effects of Anti-MCV Antibodies, D-dimer and Disease Activity
DOI:
https://doi.org/10.36320/ajb/v17.i2.19429Keywords:
Rheumatoid Arthritis, Thrombosis, D-dimer, Inflammatory Markers, Anti-MCV AntibodyAbstract
Rheumatoid arthritis (RA) carries an elevated risk of thrombotic complications, a major contributor to cardiovascular morbidity in this population. This case-control study aimed to identify predictive factors for thrombosis risk in RA and D-dimer roles, focusing on anti-mutated citrullinated vimentin (anti-MCV) antibodies and disease activity. Sixty-five RA patients and 25 age-matched female controls were recruited from Al-Sadder Teaching Hospital, Iraq (September–November 2024). Disease activity was assessed via DAS28-CRP, alongside biomarkers (CRP, ESR, D-dimer, anti-MCV), lipid profiles, and platelet counts.
RA patients exhibited significantly elevated CRP (9.19 vs. 2.45 mg/L, p<0.0001), D-dimer (0.66 vs. 0.29 μg/mL, p<0.001), anti-MCV (7.96 vs. 2.63 U/mL, p<0.001), and ESR (38.34 vs. 18.99 mm/hr, p<0.001) compared to controls. Higher disease activity (DAS28-CRP ≥3.25) correlated with older age (OR:7.600; 95%CI:2.173–26.583), elevated CRP (OR:7.000; 95%CI:3.171–15.454), and D-dimer (OR:13.176; 95%CI:2.676–64.879). Anti-MCV levels showed a weaker association (OR:3.846; 95%CI:0.452–32.695, p=0.036). ROC analysis identified CRP (AUC:0.99, sensitivity:100%, specificity:94%) and D-dimer (AUC:0.87) as robust discriminators of moderate-to-high disease activity, while anti-MCV demonstrated poor discriminatory capacity (AUC:0.60, p=0.334).
Correlation analyses revealed strong associations between DAS28-CRP and CRP (r=0.871), D-dimer (r=0.792), and ESR (r=0.541), but only a modest link with anti-MCV (r=0.313).
In conclusion, systemic inflammation (CRP, D-dimer) and age, rather than anti-MCV, are critical predictors of thrombosis risk in RA. Anti-MCV’s limited discriminatory utility suggests its role in RA pathophysiology may not directly translate to thrombosis risk stratification. These findings underscore the importance of integrating inflammatory biomarkers into RA management protocols to address cardiovascular morbidity.
Downloads
References
1. Molander, V., Bower, H., Frisell, T., & Askling, J. (2021). Risk of venous thromboembolism in rheumatoid arthritis, and its association with disease activity: a nationwide cohort study from Sweden. Annals of the rheumatic diseases, 80(2), 169–175. https://doi.org/10.1136/annrheumdis-2020-218419
2. Weitz, J. I., Szekanecz, Z., Charles-Schoeman, C., Vranic, I., Sahin, B., Paciga, S. A., Wang, Z., Hyde, C., & Martin, D. A. (2022). Biomarkers to predict risk of venous thromboembolism in patients with rheumatoid arthritis receiving tofacitinib or tumour necrosis factor inhibitors. RMD open, 8(2), e002571. https://doi.org/10.1136/rmdopen-2022-00257
3. Choe, J. Y., Lee, C. U., & Kim, S. K. (2023). Association between Novel Hematological Indices and Measures of Disease Activity in Patients with Rheumatoid Arthritis. Medicina (Kaunas, Lithuania), 59(1), 117. https://doi.org/10.3390/medicina59010117
4. Lin, Y. J., Anzaghe, M., & Schülke, S. (2020). Update on the Pathomechanism, Diagnosis, and Treatment Options for Rheumatoid Arthritis. Cells, 9(4), 880. https://doi.org/10.3390/cells9040880
5. Ketfi, C., Boutigny, A., Mohamedi, N., Bouajil, S., Magnan, B., Amah, G., & Dillinger, J. G. (2021). Risk of venous thromboembolism in rheumatoid arthritis. Joint bone spine, 88(3), 105122. https://doi.org/10.1016/j.jbspin.2020.105122
6. Huang, J., Zeng, T., Zhang, X., Tian, Y., Wu, Y., Yu, J., Pei, Z., Liu, Y., Hu, T., & Tan, L. (2020). Clinical diagnostic significance of 14-3-3η protein, high-mobility group box-1, anti-cyclic citrullinated peptide antibodies, anti-mutated citrullinated vimentin antibodies and rheumatoid factor in rheumatoid arthritis. British journal of biomedical science, 77(1), 19–23. https://doi.org/10.1080/09674845.2019.1658425
7. Omair, M. A., Alkhelb, S. A., Ezzat, S. E., Boudal, A. M., Bedaiwi, M. K., & Almaghlouth, I. (2022). Venous Thromboembolism in Rheumatoid Arthritis: The Added Effect of Disease Activity to Traditional Risk Factors. Open access rheumatology: research and reviews, 14, 231–242. https://doi.org/10.2147/OARRR.S284757
8. Hansen, E. S., Rinde, F. B., Edvardsen, M. S., Hindberg, K., Latysheva, N., Aukrust, P., Ueland, T., Michelsen, A. E., Hansen, J. B., Brækkan, S. K., & Morelli, V. M. (2021). Elevated plasma D-dimer levels are associated with risk of future incident venous thromboembolism. Thrombosis research, 208, 121–126. https://doi.org/10.1016/j.thromres.2021.10.020
9. Feng, J., Li, J., Li, Y., Jin, Y., Du, F., & Chen, X. (2022). Elevated Serum D-Dimer May Reflect the Presence of Gut Inflammation in Spondyloarthritis. Frontiers in medicine, 8, 816422. https://doi.org/10.3389/fmed.2021.816422.
10. Wajid, S. K., & Sharba, I. R. (2024). Prediction of Vitamin D and Serotonin levels with increased risk Depressive in Adolescent Students. In BIO Web of Conferences (Vol. 108, p. 04009). EDP Sciences.
https://doi.org/10.1051/bioconf/202410804009.
11. Uke, P., Maharaj, A., & Adebajo, A. (2025). A review on the epidemiology of rheumatoid arthritis: An update and trends from current literature. Best practice & research. Clinical rheumatology, 39(1), 102036. https://doi.org/10.1016/j.berh.2025.102036
12. Tang, K., Zhu, L., Shan, S., Luo, Z., Zhou, J., Ying, J., Wu, J., Shen, G., & Song, P. (2025). Global, regional and national trends in the epidemiology of rheumatoid arthritis from 1990 to 2021: an age-period-cohort effect analysis of the global burden of disease study 2021. RMD open, 11(2), e005383. https://doi.org/10.1136/rmdopen-2024-005383
13. Yan, J., Yang, S., Han, L., Ba, X., Shen, P., Lin, W., Li, T., Zhang, R., Huang, Y., Huang, Y., Qin, K., Wang, Y., Tu, S., & Chen, Z. (2023). Dyslipidemia in rheumatoid arthritis: the possible mechanisms. Frontiers in immunology, 14, 1254753. https://doi.org/10.3389/fimmu.2023.1254753
14. Weitz, J. I., Szekanecz, Z., Charles-Schoeman, C., Vranic, I., Sahin, B., Paciga, S. A., Wang, Z., Hyde, C., & Martin, D. A. (2022). Biomarkers to predict risk of venous thromboembolism in patients with rheumatoid arthritis receiving tofacitinib or tumour necrosis factor inhibitors. RMD open, 8(2), e002571. https://doi.org/10.1136/rmdopen-2022-002571
15. Khudhair H. A. A. (2023). A study of the roles of some immunological biomarkers in the diagnosis of rheumatoid arthritis. Journal of medicine and life, 16(8), 1194–1200. https://doi.org/10.25122/jml-2023-0158
16. Nelson, H. A., Martins, T. B., Saadalla, A., & Nandakumar, V. (2024). Evaluation of the clinical performance of anti-mutated citrullinated vimentin antibody and 14-3-3 eta testing in rheumatoid arthritis. Clinical chemistry and laboratory medicine, 63(4), 790–796. https://doi.org/10.1515/cclm-2024-1112
17. Choe, J. Y., Lee, C. U., & Kim, S. K. (2023). Association between Novel Hematological Indices and Measures of Disease Activity in Patients with Rheumatoid Arthritis. Medicina (Kaunas, Lithuania), 59(1), 117. https://doi.org/10.3390/medicina59010117
18. Isoda, K., Tsuji, S., Harada, Y., Yoshimura, M., Nakabayashi, A., Sato, M., Nagano, H., Kim, D. S., Hashimoto, J., & Ohshima, S. (2023). Potential of the prognostic nutritional index to determine the risk factor for severe infection in elderly patients with rheumatoid arthritis. Modern rheumatology, 33(1), 88–95. https://doi.org/10.1093/mr/roac001
19. Yoshimura, M., Fujieda, Y., Sugawara, M., Kono, M., Kato, M., Yokota, I., Amengual, O., Ito, Y. M., & Atsumi, T. (2022). Disease activity as a risk factor for venous thromboembolism in rheumatoid arthritis analysed using time-averaged DAS28CRP: a nested case-control study. Rheumatology international, 42(11), 1939–1946. https://doi.org/10.1007/s00296-022-05121-4
20. Harbsmeier, A. N., Altintas, I., Iversen, K., Andersen, O., & Nehlin, J. O. (2023). Biomarkers and the post-thrombotic syndrome: A systematic review of biomarkers associated with the occurrence of the post-thrombotic syndrome after lower extremity deep venous thrombosis. Phlebology, 38(9), 577–598. https://doi.org/10.1177/02683555231186681
21. Alsaleh, S., & Sharba, I. R. (2024). Association of IL-17 with D-dimer and Fibrinogen, as a Risk Factor for Thromboembolism in Psoriasis Patients. Magazine of Al-Kufa University for Biology, 16(3). https://doi.org/10.36320/ajb/v16.i3.17304
22. Aripova, N., Kremer, J. M., Pappas, D. A., Reed, G., England, B. R., Robinson, B. H., Curtis, J. R., Thiele, G. M., & Mikuls, T. R. (2024). Anti-citrullinated protein antibody profiles predict changes in disease activity in patients with rheumatoid arthritis initiating biologics. Rheumatology (Oxford, England), 63(2), 542–550. https://doi.org/10.1093/rheumatology/kead260
23. Omair, M. A., Alkhelb, S. A., Ezzat, S. E., Boudal, A. M., Bedaiwi, M. K., & Almaghlouth, I. (2022). Venous Thromboembolism in Rheumatoid Arthritis: The Added Effect of Disease Activity to Traditional Risk Factors. Open access rheumatology: research and reviews, 14, 231–242. https://doi.org/10.2147/OARRR.S284757
Downloads
Published
Issue
Section
License
Copyright (c) 2025 Asmaa Abdulrasool Gaafar
This work is licensed under a Creative Commons Attribution 4.0 International License.
which allows users to copy, create extracts, abstracts, and new works from the Article, alter and revise the Article, and make commercial use of the Article (including reuse and/or resale of the Article by commercial entities), provided the user gives appropriate credit (with a link to the formal publication through the relevant DOI), provides a link to the license, indicates if changes were made and the licensor is not represented as endorsing the use made of the work.
